Gilead Sciences told by FDA to pause patient enrollment in leukemia drug trials
Gilead Sciences, Inc. (NASDAQ:GILD) said the Food and Drug Administration (FDA) has put a clinical hold on its studies evaluating its investigation anti-CD47 immunotherapy magrolimab for acute myel...
US FDA puts Gilead Sciences blood cancer drug studies on hold
Gilead Sciences said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on initiating new patients in the U.S. studies for drug to treat a type of blood cancer.
Gilead says FDA hits pause on study of leukemia treatment
Gilead Sciences Inc. GILD, -0.81% said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute myeloid leukemia. Screening...
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Gilead ties up with Tentarix for cancer, inflammatory disease therapies
Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.
2 High-Yield Dividend Stocks to Buy on the Dip
Despite their falling stock prices, both of these companies have solid prospects. Pfizer has been busy making deals -- something that is already paying off.
Related Companies